₹885.2 -17.2 -1.9%
Last Trade - 13/04/21
| Market Cap | £6.93bn |
| Enterprise Value | £6.86bn |
| Revenue | £1.84bn |
| Position in Universe | 59th / 3106 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 113,454 | 137,901 | 146,302 | 152,193 | 163,624 | 171,320 | 195,044 | 209,653 | +8.6% | ||
| -15.7 | +14.4 | +4.2 | +25.7 | -4.7 | -5.6 | +60.7 | +7.15 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 17, 1935 |
| Public Since | November 3, 1994 |
| No. of Shareholders: | 242,917 |
| No. of Employees: | 24,034 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | S&P BSE 100 , Nifty 50 , |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 806,463,279 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Mumbai Central, MUMBAI, 400013, India |
| Web | https://www.cipla.com/ |
| Phone | +91 22 24826000 |
| Contact | Naveen Bansal (IR Contact Officer) |
| Auditors | Walker Chandiok & Co LLP |
As of 13/04/21, shares in Cipla are trading at ₹885.2, giving the company a market capitalisation of £6.93bn. This share price information is delayed by 15 minutes.
Shares in Cipla are currently trading at ₹885.2 and the price has moved by 49.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cipla price has moved by -6.1% over the past year.
Of the analysts with advisory recommendations for Cipla, there are there are currently 19 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cipla is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Cipla is scheduled to issue upcoming financial results on the following dates:
Cipla does not currently pay a dividend.
Cipla does not currently pay a dividend.
Cipla does not currently pay a dividend.
To buy shares in Cipla you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Cipla are currently trading at ₹885.2, giving the company a market capitalisation of £6.93bn.
Here are the trading details for Cipla:
Based on an overall assessment of its quality, value and momentum, Cipla is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Cipla are currently priced at ₹885.2. At that level they are trading at 8.81% discount to the analyst consensus target price of 0.00.
Analysts covering Cipla currently have a consensus Earnings Per Share (EPS) forecast of 31.803 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cipla. Over the past six months, the relative strength of its shares against the market has been -6.73%. At the current price of ₹885.2, shares in Cipla are trading at 15.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cipla PE ratio based on its reported earnings over the past 12 months is 31.95. The shares are currently trading at ₹885.2.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cipla's management team is headed by:
Here are the top five shareholders of Cipla based on the size of their shareholding:
